This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Bafiertam
Generic Name
Monomethyl fumarate
DrugBank Accession Number
DB14219
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental, Investigational
Structure
Weight
Average: 130.099
Monoisotopic: 130.026608673
Chemical Formula
C5H6O4
Synonyms
  • Fumaric acid monomethyl ester
  • Methyl hydrogen fumarate
  • MMF
  • Monomethyl fumarate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Monomethyl fumarate.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Monomethyl fumarate.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Monomethyl fumarate.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Monomethyl fumarate.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Monomethyl fumarate.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Monomethyl fumarate.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Monomethyl fumarate.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Monomethyl fumarate.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Monomethyl fumarate.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Monomethyl fumarate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BafiertamCapsule95 mg/1OralBanner Life Sciences LLC2020-04-28Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as fatty acid esters. These are carboxylic ester derivatives of a fatty acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acid esters
Direct Parent
Fatty acid esters
Alternative Parents
Unsaturated fatty acids / Dicarboxylic acids and derivatives / Methyl esters / Enoate esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Alpha,beta-unsaturated carboxylic ester / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Enoate ester / Fatty acid ester / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
45IUB1PX8R
CAS number
2756-87-8
InChI Key
NKHAVTQWNUWKEO-NSCUHMNNSA-N
InChI
InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+
IUPAC Name
(2E)-4-methoxy-4-oxobut-2-enoic acid
SMILES
COC(=O)\C=C\C(O)=O

References

General References
Not Available
ChemSpider
4520322
BindingDB
50342426
RxNav
1546433
ChEMBL
CHEMBL589586
ZINC
ZINC000004416885

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
1CompletedTreatmentMultiple Sclerosis1
1CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)2
Not AvailableWithdrawnNot AvailableRelapsing Remitting Multiple Sclerosis (RRMS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral95 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US9511043No2016-12-062035-02-27US flag
US9326965No2016-05-032035-02-27US flag
US9814692No2017-11-142035-02-27US flag
US9636318No2017-05-022035-02-27US flag
US9814691No2017-11-142035-02-27US flag
US10105336No2018-10-232035-02-27US flag
US9820961No2017-11-212035-02-27US flag
US10098863No2018-10-162035-02-27US flag
US9566259No2017-02-142035-02-27US flag
US9636319No2017-05-022035-02-27US flag
US10105337No2018-10-232035-02-27US flag
US9326947No2016-05-032035-02-27US flag
US9820960No2017-11-212035-02-27US flag
US9517209No2016-12-132035-02-27US flag
US10105335No2018-10-232035-02-27US flag
US10918615No2021-02-162035-08-12US flag
US10918616No2021-02-162035-06-03US flag
US10918617No2021-02-162035-08-10US flag
US10945985No2021-03-162035-08-14US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility40.1 mg/mLALOGPS
logP0.39ALOGPS
logP0.34ChemAxon
logS-0.51ALOGPS
pKa (Strongest Acidic)3.12ChemAxon
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity29.38 m3·mol-1ChemAxon
Polarizability11.61 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at July 04, 2018 21:10 / Updated at February 21, 2021 18:54